Radiopharmaceuticals Market: Will Japan (Expected to Register an Attractive Growth Rate Throughout the Forecast Period) Beat Current Market Leader North America? - Global Industry Analysis and Opportunity Assessment, 2016-2026
- Healthcare, Pharmaceuticals and Medical devices
- No. of Pages: 228
- Published: 2017-02-08
- Report Code: REP-GB-1992
-
Format:
An Incisive, In-depth Analysis on the Radiopharmaceuticals Market
This study offers a comprehensive, 360 degree analysis on the Radiopharmaceuticals market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Radiopharmaceuticals market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
North America is anticipated to be the most attractive regional market in the global radiopharmaceuticals market
North America accounted for more than 40% market share in the global radiopharmaceuticals market in 2016 and is expected to witness an increase of more than 100 BPS in its market share over the forecast period. In terms of Y-o-Y growth, North America dominated the global radiopharmaceuticals market and was valued at more than US$ 2,000 Mn in 2015. The market is expected to expand at 6.2% CAGR over the projected period to reach more than US$ 4,000 Mn by the end of 2026. The North America radiopharmaceuticals market is estimated to represent absolute $ opportunity of more than US$ 100 Mn in 2017 over 2016. The growth is stagnant and slow due to major reactors having been shut down in Canada and new reactors installed in place of old ones for better production of radioisotope. North America is expected to be the most lucrative market in the global radiopharmaceuticals market, recording an attractiveness index of 3.6.
Significant growth in the number of cancer and cardiovascular diseases patients in North America is expected to boost the global radiopharmaceuticals market
Widespread availability of SPECT and PET scanning machines will result in a growing number of radio diagnostic and radio therapeutics events in North America. For instance, the number of PET scanning machines installed per head of population in North America are more compared to that installed in Europe, thus leading to increased usage of radiotracers in the region. This growth in North America is expected to continue along with continuous technological improvements in PET scanning devices. The high level of awareness and accessibility to these machines is expected to account for high revenue generation in North America. This factor is boosting the overall growth of the global radiopharmaceuticals market. The other factor impacting the global radiopharmaceuticals market is the rising prevalence of cancer in North America. This has significantly increased the number of nuclear medicine procedures performed in the region and this is the precise reason that the market for radiopharmaceuticals is steadily growing in North America. There has been a rising number of cardiovascular diseases among the people in North America due to aging population, unhealthy food habits and rising obesity. The increasing number of cardiovascular patients is expected to boost the sales of radiopharmaceuticals, which would eventually create growth in the global radiopharmaceuticals market.
Gallium-68 and Lutetium 177 sub-segments of the radioisotope segment are likely to dominate the North America radiopharmaceuticals market
Gallium-68 and Lutetium 177 are dominant sub-segments of the radioisotope segment in North America. Gallium-68 has gained immense popularity since the last one year in the field of nuclear medicine, especially in the diagnosis and evaluation of prostate cancer. This is in heavy reliance with incorporation of several technological leaps and entry of new radiotracer- 68Ga-PSMA-11, developed by the University of Heidelberg. Additionally, marketing authorisation of the first 68Ge/68Ga generator, manufactured by the German company Eckert & Ziegler, has also positively impacted the penetration of 68Ga-PSMA-11 tracer in the treatment of prostate cancer in North America. Despite a shorter half-life, Gallium-68 has an ideal profile as a PET imaging agent. Several manufacturers in North America are focussing on introducing cold kits for the 68Ga-labeling of tracers (ANMI, Belgium), thus opening the gateways for 68Ga in PET scanning. Iodine-131, a therapeutic radiotracer continues to be the ideal tracer for the treatment of not only thyroid cancer but also other therapeutic indications. However it is being slowly replaced by Lutetium-177 (Lu-177) in North America. Lu-177, low-energy β-particle emitter is identified to be one of the emerging radiotracers for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) and neuroendocrine tumors.
Market share of companies operating in the global radiopharmaceuticals market
The global radiopharmaceuticals market is highly consolidated with a few companies that offer advanced technology systems and nuclear medicines for treating diseases. However, the global market is dominated by top five players accounting for over 89% share. Siemens Healthineers accounted for the largest share of around 41.2% of the global market in 2015. The company dominated the market owing to its diversified product portfolio, extensive geographical presence, and acquisition strategies. GE Healthcare accounted for the second largest share of around 30.1% and Mallinckrodt plc. accounted for the third largest share of around 9% in the global radiopharmaceuticals market.
In a new publication – “Radiopharmaceuticals Market: Global Industry Analysis and Opportunity Assessment, 2016-2026,” Future Market Insights forecasts the global radiopharmaceuticals market for a projected period of 10 years. This exclusive report offers in-depth analysis of market opportunities in the global radiopharmaceutical market. While studying this market, we have covered key industry events and have come to a conclusion that radiopharmaceutical manufacturers are increasingly adopting various strategies to increase the production capacity of their plants to handle requirements from end users.
The report also understands the growth and performance of the key segments of the global radiopharmaceuticals market. Through an extensive research, the analysts have studied how the different market dynamics are likely to impact the current and future scenario of the global radiopharmaceuticals market, thereby providing useful insights to market players to plan their differentiating strategies capable of evolving with the changing market landscape. The report covers the global radiopharmaceuticals market performance in terms of revenue contribution from various segments. This report also includes Future Market Insights’ exclusive analysis of key trends, drivers, restraints and opportunities, which are influencing the growth of the global radiopharmaceutical market. Impact analysis of key growth drivers and restraints are included in this report to better equip and arm clients with crystal clear decision-making insights.
Key strategic recommendations to new and existing market players is the uniqueness of this report
Primarily, the report takes an overview of the global radiopharmaceuticals market. The overview mainly consists of market taxonomy and a section underlining factors influencing the growth of the global radiopharmaceuticals market. Yearly change in inflation rate has not been considered while forecasting market numbers. A bottom-up approach has been used to assess market numbers for each product category while a top-down approach has been used to counter-validate the reached numbers while forecasting the global radiopharmaceuticals market. Macroeconomic indicators such as healthcare industry outlook, healthcare spending and Gross Domestic Product coupled with disease epidemiology and test type have been considered to arrive at the indicated market numbers.
Impact analysis of key regional growth drivers and restraints based on the weighted average model along with key region-specific trends is also included in the report to better equip clients with information and hidden insights. Future Market Insights analysts have provided key strategic recommendations for both existing and new players in the global radiopharmaceuticals market to emerge sustainably profitable. The report further covers the competitive landscape that provides a dashboard view of companies that manufacture and provide services in the global radiopharmaceuticals market. The report contains company profiles of some of the key players and a strategic overview of mergers and acquisitions along with their expansion plans across various regions.
The subsequent sections analyse the global radiopharmaceuticals market on the basis of radioisotope, region, source, end user and by application, and present a forecast for the period 2016–2026. The global radiopharmaceuticals market is segmented as follows:
|
By Radioisotope |
By Region |
By Source |
By End User |
By Application |
|---|---|---|---|---|
|
|
|
|
|
Research methodology
To arrive at the market size, the report considers the number of nuclear medicine procedures in each application segment (oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology and others) across geographies. The forecast presented here assesses the total revenue of the global radiopharmaceuticals market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the global market, we have triangulated the outcome on the basis of supply and demand side analysis. The report also takes into consideration year-on-year growth to understand the predictability of the market and to identify the right opportunities across the global radiopharmaceuticals market.
The global market for radiopharmaceuticals is split into various categories and all these segments have been analysed in terms of basis point share (BPS) to understand individual segments’ relative contribution to market growth. This level of information is important to identify key trends in the global radiopharmaceuticals market. Another useful feature of this report is the analysis of all market segments and their corresponding revenue forecast in terms of absolute dollar opportunity, critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources in the global radiopharmaceuticals market.
Radiopharmaceuticals Market Reports - Table of Contents
1. Executive Summary
18. Assumptions and Acronyms Used
19. Research Methodology
Radiopharmaceuticals Market Reports - List of Tables
Table 1: Global Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 2: Global Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 3: Global Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 4: Global Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 5: Global Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2026
Table 6: North America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 7: North America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 8: North America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 9: North America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 10: North America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 11: Latin America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 12: Latin America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 13: Latin America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 14: Latin America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 15: Latin America Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 16: Western Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 17: Western Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 18: Western Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 19: Western Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 20: Western Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 21: Eastern Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 22: Eastern Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 23: Eastern Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 24: Eastern Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 25: Eastern Europe Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 26: APEJ Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 27: APEJ Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 28: APEJ Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 29: APEJ Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 30: APEJ Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 31: Japan Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 32: Japan Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 33: Japan Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 34: Japan Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 35: Japan Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 36: MEA Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 37: MEA Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Radioisotope Segment, 2015–2026
Table 38: MEA Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Application, 2015–2026
Table 39: MEA Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By Source, 2015–2026
Table 40: MEA Radiopharmaceutical Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Radiopharmaceuticals Market Reports - List of Figures
Figure 1: Global Radiopharmaceutical Market Value Share and BPS Analysis By Radioisotope, 2016 & 2026
Figure 2: Global Radiopharmaceutical Market Y-o-Y Growth Comparison By Radioisotope, 2015 – 2026
Figure 3: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Technetium-99 Radioisotope Segment, 2015 – 2026
Figure 4: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Fluorine-18 Radioisotope Segment, 2015 – 2026
Figure 5: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Iodine-131 Radioisotope Segment, 2015 – 2026
Figure 6: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Leuteteium-177 Radioisotope Segment, 2015 – 2026
Figure 7: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Yttrium-90 Radioisotope Segment, 2015 – 2026
Figure 8: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Gallium-68 Radioisotope Segment, 2015 – 2026
Figure 9: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Gallium-67 Radioisotope Segment, 2015 – 2026
Figure 10: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Rubidium-82 Radioisotope Segment, 2015 – 2026
Figure 11: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Iodine-123 Radioisotope Segment, 2015 – 2026
Figure 12: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Iodine-125 Radioisotope Segment, 2015 – 2026
Figure 13: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Indium-111 Radioisotope Segment, 2015 – 2026
Figure 14: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Others Radioisotope Segment, 2015 – 2026
Figure 15: Global Radiopharmaceutical Market Attractiveness Analysis By Radioisotope, 2016–2026
Figure 16: Global Radiopharmaceutical Market Value Share and BPS Analysis By Application, 2016 & 2026
Figure 17: Global Radiopharmaceutical Market Y-o-Y Growth Comparison By Application, 2015 – 2026
Figure 18: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Oncology Application Segment, 2015 – 2026
Figure 19: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Cardiology Application Segment, 2015 – 2026
Figure 20: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Gastroenterology Application Segment, 2015 – 2026
Figure 21: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Endocrinology Application Segment, 2015 – 2026
Figure 22: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Neurology
Figure 23: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Nephrology Application Segment, 2015 – 2026
Figure 24: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Others Application Segment, 2015 – 2026
Figure 25: Global Radiopharmaceutical Market Attractiveness Analysis By Application, 2016–2026
Figure 26: Global Radiopharmaceutical Market Value Share and BPS Analysis By Source, 2016 & 2026
Figure 27: Global Radiopharmaceutical Market Y-o-Y Growth Comparison By Application, 2015 – 2026
Figure 28: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Cyclotrons Source Segment, 2015 – 2026
Figure 29: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Nuclear Reactors Source Segment, 2015 – 2026
Figure 30: Global Radiopharmaceutical Market Attractiveness Analysis By Source, 2016–2026
Figure 31: Global Radiopharmaceutical Market Value Share and BPS Analysis By End User, 2016 & 2026
Figure 32: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Diagnostic Imaging Centers End User Segment, 2015 – 2026
Figure 33: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) Ambulatory Surgical Centers End User Segment, 2015 – 2026
Figure 34: Global Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn) By Cancer Research Institute End User Segment, 2015 – 2026
Figure 35: Global Radiopharmaceutical Market Attractiveness Analysis By End User, 2016–2026
Figure 36: Global Radiopharmaceutical Market Value Share and BPS Analysis By End User, 2016 & 2026
Figure 37: Global Radiopharmaceutical Market Y-o-Y Growth Comparison By End User, 2015 – 2026
Figure 38: North America Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 39: Latin America Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 40: Western Europe Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 41: Eastern Europe Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 42: APEJ Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 43: Japan Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 44: MEA Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 45: Global Radiopharmaceutical Market Attractiveness Analysis By Region, 2016–2026
Figure 46: North America Radiopharmaceutical Market Value Share and BPS Analysis By Country, 2016 & 2026
Figure 47: North America Radiopharmaceutical Market Y-o-Y Growth Comparison By Country, 2015 – 2026
Figure 48: U.S. Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 49: Canada Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 50: North America Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Figure 51: Latin America Radiopharmaceutical Market Value Share and BPS Analysis By Country, 2016 & 2026
Figure 52: Latin America Radiopharmaceutical Market Y-o-Y Growth Comparison By Country, 2015–2026
Figure 53: Brazil Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 54: Mexico Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 55: Rest of Latin America Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 56: Latin America Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Figure 57: Western Europe Radiopharmaceutical Market Value Share and BPS Analysis By Country, 2016 & 2026
Figure 58: Western Europe Radiopharmaceutical Market Y-o-Y Growth Comparison By Country, 2015 – 2026
Figure 59: U.K. Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 60: France Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 61: Germany Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 62: Italy Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 63: Spain Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 64: Nordics Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 65: BENELUX Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 66: Rest of Western Europe Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 67: Western Europe Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Figure 68: Eastern Europe Radiopharmaceuticals Market Value Share and BPS Analysis By Country, 2015 & 2026
Figure 69: Eastern Europe Radiopharmaceuticals Market Y-o-Y Growth Comparison By Country, 2015–2026
Figure 70: Russia Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 71: Poland Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 72: Rest Eastern Europe Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 73: Eastern Europe Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Figure 74: APEJ Radiopharmaceuticals Market Value Share and BPS Analysis By Country, 2016 & 2026
Figure 75: APEJ Radiopharmaceuticals Market Y-o-Y Growth Comparison By Country, 2015–2026
Figure 76: China Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 77: India Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 78: Australia and New Zealand Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 79: ASEAN Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 80: APEJ Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Figure 81: Japan Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 82: MEA Radiopharmaceutical Market Value Share and BPS Analysis By Country, 2016 & 2026
Figure 83: MEA Radiopharmaceutical Market Y-o-Y Growth Comparison By Country, 2015–2026
Figure 84: GCC Countries Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 85: South Africa Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 86: Rest of MEA Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 87: Canada Radiopharmaceutical Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 88: MEA Radiopharmaceutical Market Attractiveness Analysis By Country, 2016–2026
Get in touch
Harish Tiwari
Global Head - Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.